| abstract |
The present invention is a combination of a first component (a) which is a 5-HT reuptake inhibitor and a second component (b) which is a selective 5-HT1A antagonist according to formula I, wherein R1 is n-propyl or cyclobutyl refers to; R2 is isopropyl, tertiary butyl, cyclobutyl, cyclopentyl or cyclohexyl; R3 is hydrogen; R4 represents hydrogen or methyl; The combination of (R) -enantiomer as the free base or its pharmaceutically acceptable salts, their preparation, their pharmaceutical formulations containing said combinations, the use of said combinations for effective treatment of depression, anxiety and OCD, It also relates to a device comprising these combinations. |